Xianling Zhou, Heng Shi, Shiping Zhu, Haixia Wang, Shengyun Sun
AIMS/INTRODUCTION: The union of dipeptidyl peptidase-4 (DPP-4) inhibitors and insulin in patients with type 2 diabetes (T2D) and chronic kidney disease (CKD) provides satisfactory glucose management without increasing adverse events (AEs). This research appraised the therapeutic effect and safety of combination therapy in patients with T2D and CKD. MATERIALS AND METHODS: We did a meta-analysis of randomized controlled trials (RCTs) to analyze AEs, hypoglycemia, serious adverse events (sAEs), severe hypoglycemia, estimated glomerular filtration rate (eGFR), fasting plasma glucose (FPG), glycated hemoglobin (HbA1C), insulin dose, low density lipoprotein cholesterol (LDL-C), uric acid (UA), and weight between combination treatment groups and control groups by searching the Cochrane Library, Excerpta Medica Database (Embase), PubMed, and Web of Science databanks until October 2020...
September 22, 2021: Journal of Diabetes Investigation